title: Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis.
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000276:immunology; D000068582:Certolizumab Pegol; D004334:Drug Administration Schedule; D016527:Drug Costs; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D018664:Interleukin-12 / Q000037:antagonists & inhibitors / Q000378:metabolism; D053759:Interleukin-23 / Q000037:antagonists & inhibitors / Q000378:metabolism; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism; D000069549:Ustekinumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D007166:Immunosuppressive Agents; D053759:Interleukin-23; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12; D011092:Polyethylene Glycols; D000069549:Ustekinumab; D000068582:Certolizumab Pegol